Russian national clinical recommendations for diagnosis and treatment of anemia in chronic kidney disease

Russian national clinical recommendations for diagnosis and treatment of anemia in chronic kidney disease are renewal of the national recommendations issued in 2006 by Anemia Working Group previously and accumulate information from large multicenter clinical trials and re-analysis and meta-analysis of data published until December 2015. The working group considered statements and rationales of KDIGO (2012), other national guidelines and position statements as well as Russia population feature and real practice conditions. The target level for hemoglobin is defined as 10.0-12.0 g/dl. The groups of patients, which can benefit with hemoglobin level close to lower and upper border of the target range are described. The algorithms of patient evaluation and therapy are recommended as well as the evaluation of non-responders. First line therapy in most cases is iron; the erythropoietin (EPO) dose escalation in resistant cases should be limited. The exceeding of weekly dose of 12,000 IE rarely leads to hemoglobin increase but extends the risks linked to EPO therapy. Blood transfusion is indicated in very limited number of conditions.

клинические рекомендации, анемия, препараты железа, эритропоэтин, средства, стимулирующие эритропоэз, целевой диапазон гемоглобина, гемотрансфузии, Clinical Practice Guideline, anemia, iron, erythropoietin, erythropoiesis-stimulating agent, hemoglobin target range, red cell transfusion

1. Бикбов Б.Т., Томилина Н.А. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998-2011 гг. (Отчет по данным Российского регистра заместительной почечной терапии. Часть первая). Нефрология и диализ. 2014. 16(1): 11-127.

2. Вишневский К.А., Беляев А.Е., Мироненко А.Н. Полиморбидность как предиктор летальности у пациентов, находящихся на постоянной заместительной почечной терапии гемодиализом. Нефрология. 2015. 19(4): 89-94.

3. Добронравов В.А., Смирнов А.В., Безруких А.М. и соавт. Анемия и преддиализные стадии хронической болезни почек: клиническое значение, распространенность и факторы риска. Нефрология. 2006. 10(3): 7-13.

4. Ермоленко В.М., Сбоева С.Г. Cравнительная клинико-экономическая оценка терапии анемии у больных на диализе аранеспом и мирцерой. Клиническая фармакология и терапия. 2010. 19(5): 75-77.

5. Земченков А.Ю., Конакова И.Н. Темпы прогрессирования хронической болезни почек по данным Санкт-Петербургского городского регистра ХБП. Нефрология и диализ. 2015. 17(1): 34-51.

6. Клинические практические рекомендации KDIGO по анемии при хронической болезни почек 2012. Перевод с английского А.Ю. Земченкова под редакцией

7. Е.В. Захаровой. Перевод выполнен по поручению и одобрен KDIGO. Нефрология и диализ. 2013. 15(1): 14-53.

8. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Опыт лечения анемии эритропоэтином длительного действия метоксиполиэтиленгликолем-эпоэтин бета (Мирцера) больных хронической болезнью почек на додиализном этапе. Клиническая нефрология. 2013. 1: 37-40.

9. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Анемия. 2006. 3: 3-19.

10. Фишбейн С.,Паганини Э.П. Гематологические аномалии. Руководство по диализу. Редакторы: Джон Т. Даугирдас, Питер Дж. Блейк, Тодд С. Инг. Пер. с англ. под ред. А.Ю. Денисова и В.Ю. Шило. Третье издание. М.: Центр диализа. - Тверь: ООО “Издательство “Триада” - 2003 С. 528-546.

11. Agarwal R., Kusek JW., Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015. 88(4): 905-914.

12. Albaramki J., Hodson E.M., Craig J.C., Webster A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012. Jan 18. 1: CD007857.

13. Bailie G.R., Larkina M., Goodkin D.A. et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013. 28(10): 2570-9.

14. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998. 339(9): 584-90.

15. Drüeke T.B., Massy Z.A. Oral or intravenous iron for anemia correction in chronic kidney disease? Kidney Int. 2015. 88(4): 673-675.

16. Drüeke T.B., Locatelli F., Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006. 355(20): 2071-84.

17. Drüeke T.B., Parfrey P.S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012. 82(9): 952-60.

18. Fuller D.S., Bieber B.A., Pisoni R.L. et al. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol. 2015 Nov 18. pii: ASN.2015060673. [Epub ahead of print].

19. Fuller D.S., Pisoni R.L., Bieber B.A. et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis. 2013. 62(6): 1213-6.

20. Hahn D., Cody J.D., Hodson E.M. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev. 2014 May 28. 5: CD003895.

21. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012. Suppl. 2(4): 279-335.

22. Kliger A.S., Foley R.N., Goldfarb D.S. et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013. 62(5): 849-59.

23. Koulouridis I., Alfayez M., Trikalinos T.A. et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013. 61(1): 44-56.

24. Locatelli F., Aljama P., Canaud B. et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010. 25(9): 2846-50.

25. Locatelli F., Bárány P., Covic A. et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. ERA-EDTA ERBP Advisory Board. Nephrol Dial Transplant. 2013. 28(6): 1346-59.

26. Macdougall I.C., Bock A., Carrera F. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014. 29(11): 2075-84.

27. Macdougall I.C., Bock A., Carrera F. et al. The FIND-CKD study - a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant. 2014. 29(4): 843-50.

28. Moist L.M., Troyanov S., White C.T. et al. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guidelinefor Anemia in CKD. Am J Kidney Dis. 2013. 62(5): 860-73.

29. Palmer S.C., Saglimbene V., Mavridis D. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014. Dec 8. 12: CD010590.

30. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009. 19. 361(21): 2019-32.

31. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006. 355(20): 2085-98.